Last Update Time:
04-Mar-2025 12:01:50
ISIN:
INE563J01010
Sector:
Chemicals
Symbol:
ASTEC
Astec LifeSciences Limited
₹693.85
₹-6.30
(-0.90%)
▼
Prev. Close
₹700.15
Open
₹703.70
Close
₹0.00
Range
₹659.16 - ₹728.54
High
₹718.90
Low
₹690.25
Ind. Close
₹0.00
VWAP
₹704.58
The current stock price of Astec LifeSciences Limited is ₹693.85, with a target price range between ₹659.16 and ₹728.54. The stock has experienced a price change of ₹-6.30 (-0.90%), reflecting recent market volatility.
Today's opening price was ₹703.70, while the previous close stood at ₹700.15.
The market trend suggests a potential downtrend, with investors exercising caution due to recent declines. Analysts recommend closely monitoring support levels.
For real-time stock market updates, live share prices, and stock analysis, stay tuned. Understanding key stock metrics like VWAP, high-low range, and market momentum can help traders make informed investment decisions.
Astec LifeSciences Limited Price Chart
Astec LifeSciences Limited Pre Open Market Overview: 04-Mar-2025
Key Metrics:
- IEP (Indicative Equilibrium Price): 703.7
- Previous Close Price: 700.15
- Change: 3.55%
- Total Traded Volume: 81
- Total Buy Quantity: 1,627
- Total Sell Quantity: 1,219
| Price | Buy Qty | Sell Qty |
|---|---|---|
| 690.25 | 3.00 | 0.00 |
| 690.30 | 1.00 | 0.00 |
| 700.00 | 7.00 | 0.00 |
| 703.70 | 25.00 | 0.00 |
| 705.00 | 251.00 | 0.00 |
| 710.65 | 0.00 | 240.00 |
| 713.00 | 0.00 | 4.00 |
| 718.90 | 0.00 | 105.00 |
| 721.15 | 0.00 | 6.00 |
| 725.00 | 0.00 | 25.00 |
ATO Data:
- Buy Quantity (ATO): 0
- Sell Quantity (ATO): 0
Order Book
| Bid | Qty | Ask | Qty |
|---|---|---|---|
| 692.25 | 3 | 693.65 | 1 |
| 692.20 | 10 | 693.85 | 1 |
| 692.15 | 34 | 694.45 | 1 |
| 692.05 | 25 | 694.50 | 2 |
| 692.00 | 12 | 694.85 | 2 |
Total Buy Quantity: 1627
Total Sell Quantity: 1219
Shareholding Patterns of Astec LifeSciences Limited
Key Trade Statistics of Astec LifeSciences Limited
| Trade Information | Details |
|---|---|
| Traded Volume (Lakhs) | 0.16 |
| Traded Value (₹ Cr.) | 1.12 |
| Total Market Cap (₹ Cr.) | 1,360.73 |
| Free Float Market Cap (₹ Cr.) | 451.62 |
| Impact cost | 0.21 |
| Quantity Traded | 12,983.00 |
| Deliverable Quantity | 8,121.00 |
| % of Quantity to Traded | 62.55 |
| Security VaR | 18.81 |
| Index VaR | N/A |
| VaR Margin | 18.81 |
| Extreme Loss Rate | 3.5 |
| Adhoc Margin | N/A |
| Applicable Margin Rate | 22.31 |
| Face Value | 10 |
Key Price Statistics of Astec LifeSciences Limited
The 52-week high for Astec LifeSciences Limited was ₹1,474.40, recorded on 08-Jul-2024. On the other hand, the 52-week low stands at ₹647.50, with the lowest value recorded on 18-Feb-2025.
The upper band for trading is ₹840.15, and the lower band is ₹560.15. The price band is 20%.
The stock's daily volatility stands at 2.88, while the annualized volatility is 55.02. The tick size for trading is ₹0.05.
| Price Information | Details |
|---|---|
| 52 Week High (08-Jul-2024) | 1,474.40 |
| 52 Week Low (18-Feb-2025) | 647.50 |
| Upper Band | 840.15 |
| Lower Band | 560.15 |
| Price Band (%) | 20 |
| Daily Volatility | 2.88 |
| Annualised Volatility | 55.02 |
| Tick Size | 0.05 |
Key Securities Statistics of Astec LifeSciences Limited
| Securities Information | Details |
|---|---|
| Status | Listed |
| Trading Status | Active |
| Date of Listing | 25-Nov-2009 |
| Adjusted P/E | 0 |
| Symbol P/E | 0 |
| Index | NA |
| Macro-Economic Sector | Commodities |
| Sector | Chemicals |
| Industry | Fertilizers & Agrochemicals |
| Basic Industry | Pesticides & Agrochemicals |
Security Status of Astec LifeSciences Limited
| Title | Details |
|---|---|
| Board Status | Main |
| Trading Segment | Normal Market |
| Session No. | - |
| Class of Shares | Equity |
| SDD Compliance | - |
| Name of Compliance Officer | - |
Announcements of Astec LifeSciences Limited
| Subject | Date |
|---|---|
| Copy of Newspaper Publication | 11-Feb-2025 |
| Integrated Filing- Financial | 10-Feb-2025 |
| Notice Of Shareholders Meetings-XBRL | 10-Feb-2025 |
| Shareholders meeting | 10-Feb-2025 |
| Copy of Newspaper Publication | 28-Jan-2025 |
| Acquisition-XBRL | 28-Jan-2025 |
| Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent | 27-Jan-2025 |
| Press Release | 27-Jan-2025 |
Corporate Actions of Astec LifeSciences Limited
| Face Value | Purpose | Ex-Date |
|---|---|---|
| 10 | Annual General Meeting | 23-Jul-2024 |
| 10 | Annual General Meeting/Dividend - Rs 1.50 Per Share | 21-Jul-2023 |
| 10 | Annual General Meeting/Dividend - Rs 1.50 Per Share | 19-Jul-2022 |
| 10 | Annual General Meeting/Dividend - Rs 1.50 Per Share | 22-Jul-2021 |
| 10 | Annual General Meeting/Dividend - Rs 1.50 Per Share | 16-Jul-2020 |
| 10 | Annual General Meeting/ Dividend - Rs 1.50 Per Share | 18-Jul-2019 |
| 10 | Annual General Meeting/Dividend- Rs 1.50 Per Share | 19-Jul-2018 |
| 10 | Annual General Meeting/Dividend - Rs 1.50 Per Share | 17-Jul-2017 |
| 10 | Annual General Meeting | 20-Jul-2016 |
| 10 | Annual General Meeting/ Dividend - Rs 1.25/- Per Share | 15-Sep-2015 |
| 10 | Annual General Meeting / Dividend - Re 1/- Per Share | 15-Sep-2014 |
| 10 | Annual General Meeting / Dividend Re 0.75/- Per Share | 02-Sep-2013 |
| 10 | Annual General Meeting/Dividend Re 0.50 Per Share | 13-Sep-2012 |
| 10 | Annual General Meeting And Dividend Re.0.50 Per Share | 15-Sep-2011 |
| 10 | Annual General Meeting And Dividend Re.1/- Per Share | 12-Aug-2010 |
Board Meetings of Astec LifeSciences Limited
Financial Results of Astec LifeSciences Limited
Company Directory of Astec LifeSciences Limited
| Web Address | Office | Address | City |
|---|---|---|---|
| N/A | Registered Office | "Godrej One", 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East) Mumbai | MUMBAI |
| N/A | Transfer Agent | Bigshare Services Private Limited E-2 & 3 Ansa Industrial Estate, Sakivihar Road, Sakinaka, Andheri (East), | MUMBAI |
Insider Trading of Astec LifeSciences Limited
| Reg. Clause | Acq./Disp. | Sec. Value | Txn Type |
|---|---|---|---|
| 7(2) | Nadir Godrej | 443220098 | Buy |
| 7(2) | Tanya Dubash | 147769231 | Buy |
| 7(2) | Pirojsha Godrej | 147680540 | Buy |
| 7(2) | Nisaba Godrej | 147769231 | Buy |
| 7(2) | Balram Singh Yadav | 4770239 | Sell |
| 7(2) | GODREJ AGROVET LIMITED | 94677533 | Buy |
| 7(2) | GODREJ AGROVET LIMITED | 95087468 | Buy |
| 7(2) | GODREJ AGROVET LIMITED | 25225819 | Buy |
| 7(2) | GODREJ AGROVET LIMITED | 1764210 | Buy |
| 7(2) | GODREJ AGROVET LIMITED | 7366115 | Buy |
| 7(2) | GODREJ AGROVET LIMITED | 110490556 | Buy |
| 7(2) | GODREJ AGROVET LIMITED | 218871979 | Buy |
| 7(2) | Ashok Vishwanath Hiremath | 2903968 | Buy |
| 7(2) | Ashok Vishwanath Hiremath | 31440590 | Buy |
| 7(2) | Ashok Vishwanath Hiremath | 5224579 | Buy |
| 7(2) | Sandeep Kumar Singh | 958596 | Buy |
| 7(2) | Sandeep Kumar Singh | 956340 | Buy |
| 7(2) | Balram Singh Yadav | 1481330 | Buy |
| 7(2) | Balram Singh Yadav | 3506058 | Buy |
| 7(2) | Ramesh Pingale | 1530000 | Sell |
Annual Reports of Astec LifeSciences Limited
Investor Complaints of Astec LifeSciences Limited
Event Calendar of Astec LifeSciences Limited
| Purpose | Details |
|---|---|
| Results/Dividend | Inter alia, to transact the following business : (1) To consider and approve the Audited Annual Accounts for the year ended March 31, 2010; (2) To recommend Dividend on the Equity shares, if any. |
| Results/Others | To consider and approve amongst other items of agenda, the Unaudited Financial Results of the Company for the quarter ended June 30, 2010 after these results are reviewed by the Audit Committee. |
| Results/Others | To consider and approve amongst other items of agenda, the Unaudited Financial Results of the Company for the quarter ended September 30, 2010 after these results are reviewed by the Audit Committee. |
| Results/Dividend | Inter alia, to transact the following business : (1) To consider and approve the Audited Annual Accounts for the year ended March 31, 2011, after these accounts are reviewed by Audit Committee; (2) To recommend dividend on the Equity shares, if any. |
| Results/Others | To consider and approve amongst other items of agenda, the Unaudited Financial Results of the Company for the quarter ended June 30, 2011 after these results are reviewed by the Audit Committee. |
| Results/Others | To consider and approve amongst other items of agenda, the Unaudited Financial Results of the Company for the quarter ended September 30, 2011 after these results are reviewed by the Audit Committee. |
| Results/Others | To consider and approve amongst other items of agenda, the Unaudited Financial Results of the Company for the quarter ended December 31, 2011 after these results are reviewed by the Audit Committee. |
| Results/Dividend | Inter alia, to transact the following business: (1) To consider and approve the Standalone & Consolidated Audited Annual Accounts for the year ended March 31, 2012, after these accounts are reviewed by Audit Committee. (2) To recommend dividend on the Equity shares, if any. (3) To appoint Non-Executive & Independent Director. |
| Results/Others | To consider and approve amongst other items of agenda, the Unaudited Financial Results of the Company for the quarter ended June 30, 2012 after these results are reviewed by the Audit Committee. |
| Results/Others | To consider and approve amongst other items of agenda, the Unaudited Financial Results of the Company for the quarter ended September 30, 2012 after these results are reviewed by the Audit Committee. |
| Results/Others | To consider and approve amongst other items of agenda, the Unaudited Financial Results of the Company for the quarter ended December 31, 2012 after these results are reveiwed by the Audit Committee. |
| Results/Dividend | Inter alia, to transact the following business : (1) To consider and approve the Standalone & Consolidated Audited Annual Accounts for the Quarter & Year Ended March 31, 2013, after these accounts are reviewed by Audit Committee; (2) To recommend dividend on the Equity shares for the year ended March 31, 2013, if any. |
| Results | To consider and approve amongst other items of agenda, the Unaudited Financial Results of the Company for the quarter ended June 30, 2013 after these results are reviewed by the Audit Committee. |
| Results/Others | To consider and approve amongst other items of agenda, the Unaudited Financial Results of the Company for the quarter ended September 30, 2013 after these results are reviewed by the Audit Committee. |
| Results/Others | To consider and approve amongst other items of agenda, the Unaudited Financial Results of the Company for the quarter ended December 31, 2013 after these results are reviewed by the Audit Committee. |
| Results/Dividend | Inter alia, to transact the following business: (1) To consider and approve the Standalone & Consolidated Audited Accounts for the Quarter & Year Ended March 31, 2014, after these accounts are reviewed by Audit Committee. (2). To recommend dividend on Equity shares for the year ended March 31, 2014, if any. |
| Results/Dividend | Inter alia, to transact the following business :(1). To consider and approve the Standalone & Consolidated Audited Accounts for the Quarter & Year Ended March 31, 2014, after these accounts are reviewed by Audit Committee.(2). To recommend dividend on Equity shares for the year ended March 31, 2014, if any.(3). To discuss issuance of securities on Preferential basis by way of issue of Equity Shares/Preference Shares/Convertible Warrants/Cumulative Convertible Preference Shares/Cumulative Convertible Bonds/Debentures not exceeding Rupees 25 Crores (shall include premium thereon). (4). To increase the Authorised Capital of the Company to give effect to item no. 3 above (5). To alter Memorandum and Articles of Association of Company to give effect to item no. 3 & 4 above. |
| Results/Others | Inter-alia, to transact the following business: (1) To consider and approve the Unaudited financial accounts for the Quarter ended June 30, 2014, after these accounts are reviewed by Audit Committee.(2) To increase the Authorised Capital of the Company.(3) To alter Memorandum and Articles of Association of Company to give effect to item no.2 above. |
| Results | To consider and approve amongst other items of agenda , the Unaudited Financial Results of the Company for the quarter ended September 30, 2014 after these results are reviewed by the Audit Committee. Further the Company's Code of Conduct for (Prohibition of Insider Trading) Regulations, 1992, the Trading Window for dealing in the securities of the Company will be closed for the purpose of declaration of unaudited financial results of the Company for the quarter ended September 30, 2014 for all the Officers and Designated Employees (including Directors) of the Company from October 09, 2014 till 24 hours after the announcement of the financial results of the Company to the Stock Exchanges (both days inclusive). Accordingly all Officers and Designated Employees (including Directors) of the Company have been intimated not to enter into any transaction involving the securities of the Company during the aforesaid period of closure of Trading Window. |
| Others | To consider and approve following items of agenda: 1) To consider and approve the issue and allotment of Equity shares on Preferential basis of Rs.10,00,00,000/- (Rupees Ten Crores Only) including premium thereon, to select persons/entities on such terms and conditions and at such price not lower than the price to be determined by SEBI (ICDR) Regulations, subject to the approval of members. 2) To approve the borrowing limits of the Company in compliance with the provisions of Section 180(1)(c) of the Companies Act, 2013. 3) To approve creation of charges on the assets of the Company in compliance with the provisions of Section 180(1)(a) of the Companies Act, 2013. 4) To grant Employee Stock Options to the employees of subsidiary companies of Astec LifeSciences Limited in compliance with terms and conditions of ESOP Scheme 2012, subject to the approval of members. 5) To authorize Director of the Company or Company Secretary to obtain the approval of members by way of conducting Postal ballot for item nos. 1, 2, 3 & 4 above. 6) Any other matter with the permission of Chair. |
| Results/Others | Inter alia, to consider following business: 1) to consider and approve the Unaudited Financial Results of the Company for the quarter ended December 31, 2014, after these results are reviewed by the Audit Committee, in terms of the provisions of clause 41 of the Listing Agreement and; 2) to consider allotment of 9,25,925 Equity Shares of Rs. 10/- each fully paid-up at Rs. 108/ - per share (including a premium of Rs. 98/- per share) on preferential basis to select persons/entities belonging to Non-Promoter Group, consequent to the approval of shareholders of the Company through Postal Ballot on January 20, 2015. Private placement offer letter is being sent to the select persons/entities belonging to Non-Promoter Group, as approved by Shareholders of the Company by passing of Special Resolution through Postal Ballot on January 20, 2015. 3) Any other matter with the permission of Chair. |
| Results/Dividend | Inter alia, to transact the following business: 1. To consider and approve the Standalone & Consolidated Audited Accounts for the Quarter & Year Ended March 31, 2015, after these accounts are reviewed by Audit Committee. 2. To recommend dividend on Equity shares for the year ended March 31, 2015, if any. 3. Any other matter with the permission of chair. |
| Results/Others | To consider and approve amongst other items of agenda, the Unaudited Financial Results of the Company for the quarter ended June 30, 2015 after these results are reviewed by the Audit Committee. |
| Results/Others | To consider and approve amongst other items of agenda, the Unaudited Financial Results of the Company for the quarter ended September 30, 2015 after these results are reviewed by the Audit Committee. |
| Results/Others | To consider and approve amongst other items of agenda, the Unaudited Financial Results of the Company for the Quarter ended December 31, 2015 after these results are reviewed by the Audit Committee. |
| Results | To consider and approve the Standalone & Consolidated Audited Financial results for the Quarter & Financial Year ended March 31, 2016, after these results are reviewed by the Audit Committee. |
| Results | to, inter alia, consider and approve the Standalone and Consolidated Unaudited Financial results for the Quarter ended June 30, 2016, after these results are reviewed by the Audit Committee. |
| Results | Inter alia, consider and approve the Standalone and Consolidated Unaudited Financial results for the Quarter and Half Year ended September 30, 2016 (subject to limited review by the Statutory Auditors of the Company), after these results are reviewed by the Audit Committee. |
| Results | To, inter alia, consider and approve the Standalone and Consolidated Unaudited Financial results for the Quarter and Nine Months period ended December 31, 2016 (subject to limited review by the Statutory Auditors of the Company), after these results are reviewed by the Audit Committee. |
| Results/Dividend | To, inter alia, consider and approve the Standalone and Consolidated Audited Financial Results for the Quarter and Financial Year ended March 31, 2017, after these results are reviewed by the Audit Committee and to consider recommendation of Final Dividend on the Equity Shares of the Company for the Financial Year ended March 31, 2017, if any. |
| Results/Others | to, inter alia, consider and approve the Standalone and Consolidated Unaudited Financial Results for the Quarter ended June 30, 2017 (subject to limited review by the Statutory Auditors of the Company), after these results are reviewed by the Audit Committee. |
| Results/Others | to, inter alia, consider and approve the Standalone and Consolidated Unaudited Financial Results for the Quarter and Half Year ended September 30, 2017 (subject to limited review by the Statutory Auditors of the Company), after these results are reviewed by the Audit Committee. |
| Results | , to, inter alia, consider and approve the Standalone and Consolidated Unaudited Financial Results for the Quarter and Nine Months period ended December 31, 2017 (subject to limited review by the Statutory Auditors of the Company), after these results are reviewed by the Audit Committee. |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2018 and dividend |
| Financial Results | The meeting of the Board of Directors of the Company is scheduled on 01/08/2018, inter alias, to consider and approve the Standalone and Consolidated Unaudited Financial Results for the Quarter ended 30th June, 2018 (subject to limited review by the Statutory Auditors of the Company), after these results are reviewed by the Audit Committee.In terms of Regulation 47 of the Listing Regulations, please find enclosed herewith copies of the Notices of the Board Meeting published in newspapers, viz. Business Standard (in English Language) and Mumbai Lakshadeep (in Marathi language) today, i.e., on 25th July, 2018.Kindly take note of the above. |
| Other business matters | Inter alia, to consider and approve Scheme of Amalgamation of the Company with Godrej Agrovet Limited ( Holding Company). |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2018 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2018 |
| Financial Results/Dividend | Notice is hereby given pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (ￂﾓListing Regulationsￂﾔ), that the Meeting of the Board of Directors of Astec LifeSciences Limited (ￂﾓthe Companyￂﾔ) is scheduled to be held on Tuesday, 30th April, 2019, to, inter alia, consider and approve the Standalone and Consolidated Audited Financial Results for the Quarter and Financial Year ended 31st March, 2019, after these results are reviewed by the Audit Committee and to consider recommendation of Final Dividend on the Equity Shares of the Company for the Financial Year ended 31st March, 2019 (if any). |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2019 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2019 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2019 |
| Financial Results/Dividend | Notice is hereby given pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( Listing Regulations ), that the Meeting of the Board of Directors of Astec LifeSciences Limited ( the Company ) is scheduled to be held on Tuesday, 5th May, 2020, to, inter alia, consider and approve the Standalone and Consolidated Audited Financial Results for the Quarter and Financial Year ended 31st March, 2020, after these results are reviewed by the Audit Committee and to consider recommendation of Final Dividend on the Equity Shares of the Company, if any, for the Financial Year ended 31st March, 2020. |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2020 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2020 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2020 |
| Financial Results/Dividend | Notice is hereby given pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( Listing Regulations ), that the Meeting of the Board of Directors of Astec LifeSciences Limited ( the Company ) is scheduled to be held on Friday, 30th April, 2021, to, inter alia, consider and approve the Standalone and Consolidated Audited Financial Results for the Quarter and Financial Year ended 31st March, 2021 after these results are reviewed by the Audit Committee and to consider recommendation of Final Dividend, if any, on the Equity Shares of the Company for the Financial Year ended 31st March, 2021.In terms of Regulation 47 of the Listing Regulations, please find enclosed herewith, copies of the Notices of the Board Meeting published in newspapers, viz., Business Standard (in English language) and Mumbai Lakshadeep (in Marathi language) today, i.e., on 22nd April, 2021. |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2021 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2021 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2021 |
| Financial results | Astec LifeSciences Limited has informed the Exchange about Board Meeting to be held on 25-Jul-2022 to, inter alia, consider and approve the Standalone and Consolidated Unaudited Financial Results for the Quarter ended 30th June, 2022 (subject to limited review by the Statutory Auditors of the Company), after these results are reviewed by the Audit Committee |
| Financial results | Astec LifeSciences Limited has informed the Exchange about Board Meeting to be held on 28-Oct-2022 to consider financial statements for the period ended September 2022 |
| Fund Raising | Further to the intimation dated 11th January, 2023 regarding the Meeting of the Board of Directors of Astec LifeSciences Limited ( the Company ) scheduled to be held on Monday, 30th January, 2023 to, inter alia, consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the Quarter and Nine Months period ended 31st December, 2022, notice is hereby given pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( Listing Regulations ), that, at the said Meeting, the Board may also consider and approve issuance of Debentures or debt securities upto such limit as may be deemed appropriate and approved by the Board, subject to such other approval(s) as may be applicable. |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2022 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2023 and dividend, if any |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2023 |
| Financial Results/Fund Raising | To consider and approve the financial results for the period ended September 30, 2023 and Fund Raising |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2023 |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2024 |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2024 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2024 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2024 |
Share Transfers of Astec LifeSciences Limited
Voting Results of Astec LifeSciences Limited
| Date of Mtg. | Mtg. Type | Resolution |
|---|---|---|
| 14-DEC-2024 | Postal Ballot | Appointment of Dr. Ganapati Dadasaheb Yadav as an Independent Director of the Company |
| 14-DEC-2024 | Postal Ballot | Ratification of the Remuneration of Tapan Gaitonde & Co., Cost & Management Accountants, as the ￢ﾀﾜCost Auditors￢ﾀﾝ of the Company for the Financial Year 2024-25 |
| 14-DEC-2024 | Postal Ballot | Approval of Related Party Transactions entered into or to be entered into with Godrej Agrovet Limited (Holding Company) during the Financial Year 2024-25, beyond the Materiality threshold as provided in Regulation 23(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 |
| 14-DEC-2024 | Postal Ballot | Appointment of Mr. Arijit Mukherjee, Chief Operating Officer, as the ￢ﾀﾜManager￢ﾀﾝ of the Company (within the meaning of the Companies Act, 2013) |
| 29-JUL-2024 | AGM | Adoption of Financial Statements for the Financial Year ended 31st March, 2024 |
| 29-JUL-2024 | AGM | Ratification of Remuneration of Mr. Paresh Jaysih Sampat, Cost Accountant, Mumbai as the ￢ﾀﾜCost Auditor￢ﾀﾝ of the Company for the Financial Year ending 31st March, 2025 |
| 29-JUL-2024 | AGM | Re-appointment of Mr. Ashok V. Hiremath (DIN: 00349345) as a ￢ﾀﾜDirector￢ﾀﾝ, liable to retire by rotation, who has offered himself for re-appointment |
| 09-MAR-2024 | Postal Ballot | Re-appointment of Mr. Anurag Roy as Whole Time Director & Chief Executive Officer |
| 27-JUL-2023 | AGM | Adoption of Financial Statements for the Financial Year ended 31st March, 2023 |
| 27-JUL-2023 | AGM | Ratification of Remuneration of M/s. NNT & Co., Cost Accountants, Mumbai as the Cost Auditors |
| 27-JUL-2023 | AGM | Re-appointment of Mr. Balram Singh Yadav (DIN: 00294803) as a Director, liable to retire by rotation |
| 27-JUL-2023 | AGM | Declaration of Final Dividend on Equity Shares for the Financial Year ended 31st March, 2023 |
| 18-SEP-2022 | Postal Ballot | Appointment of Mr. Burjis Godrej (DIN: 08183082) as ￢ﾀﾜNon-Executive, Non-Independent Director￢ﾀﾝ of the Company |
| 25-JUL-2022 | AGM | Adoption of Financial Statements for the Financial Year ended 31st March, 2022 |
| 25-JUL-2022 | AGM | Approval for Increase in Remuneration of Mr. Anurag Roy, Whole Time Director & ChiefnExecutive Officer |
| 25-JUL-2022 | AGM | Ratification of Remuneration of M/s. NNT & Co., Cost Accountants, Mumbai as the ￢ﾀﾜCostnAuditors￢ﾀﾝ of the Company for the Financial Year ending 31st March, 2023 |
| 25-JUL-2022 | AGM | Re-appointment of B S R & Co. LLP, Chartered Accountants as the ￢ﾀﾜStatutory Auditors￢ﾀﾝ of the Company for a second term of 5 (Five) years |
| 25-JUL-2022 | AGM | Re-appointment of Mr. Nadir B. Godrej as a ￢ﾀﾜDirector￢ﾀﾝ, liable to retire by rotation, who has offered himself for re-appointment |
| 25-JUL-2022 | AGM | Declaration of Final Dividend on Equity Sharesnfor the Financial Year ended 31st March, 2022 |
| 26-SEP-2021 | Postal Ballot | Approval of Amendment to Employees Stock Option Scheme, 2012 (￢ﾀﾜESOP 2012￢ﾀﾝ) |
FAQs on Astec LifeSciences Limited
Disclaimer: The information provided here is for informational purposes only and should not be considered financial advice. Please do your own research and consult with a financial professional before making any investment decisions.